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Blocking endothelin-1-receptor/β-catenin circuit
sensitizes to chemotherapy in colorectal cancer
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Anna Bagnato*,1
The limited clinical response to conventional chemotherapeutics observed in colorectal cancer (CRC) may be related to the
connections between the hyperactivated β-catenin signaling and other pathways in CRC stem-like cells (CRC-SC). Here, we show
the mechanistic link between the endothelin-1 (ET-1)/ET-1 receptor (ET-1R) signaling and β-catenin pathway through the specific
interaction with the signal transducer β-arrestin1 (β-arr1), which initiates signaling cascades as part of the signaling complex.
Using a panel of patient-derived CRC-SC, we show that these cells secrete ET-1 and express ETAR and β-arr1, and that the
activation of ETAR/β-arr1 axis promotes the cross-talk with β-catenin signaling to sustain stemness, epithelial-to-mesenchymal
transition (EMT) phenotype and response to chemotherapy. Upon ETAR activation, β-arr1 acts as a transcription co-activator that
binds β-catenin, thereby promoting nuclear complex with β-catenin/TFC4 and p300 and histone acetylation, inducing chromatin
reorganization on target genes, such as ET-1. The enhanced transcription of ET-1 increases the self-sustained ET-1/β-catenin
network. All these findings provide a strong rationale for targeting ET-1R to hamper downstream β-catenin/ET-1 autocrine circuit.
Interestingly, treatment with macitentan, a dual ETAR and ETBR antagonist, able to interfere with tumor and microenvironment,
disrupts the ET-1R/β-arr1-β-catenin interaction impairing pathways involved in cell survival, EMT, invasion, and enhancing
sensitivity to oxaliplatin (OX) and 5-fluorouracil (5-FU). In CRC-SC xenografts, the combination of macitentan and OX or 5-FU
enhances the therapeutic effects of cytotoxic drugs. Together, these results provide mechanistic insight into how ET-1R coopts
β-catenin signaling and offer a novel therapeutic strategy to manage CRC based on the combination of macitentan and
chemotherapy that might benefit patients whose tumors show high ETAR and β-catenin expression.
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Colorectal cancer (CRC) is one of the main causes of tumor-
related mortality worldwide and its therapy mainly relies on
the use of conventional chemotherapeutic drugs.1 Most CRC
carry mutations leading to overactivation of the β-catenin
pathway.2 CRC stem-like cells (CRC-SC) have been shown to
be responsible for tumor propagation, metastasis and
resistance to conventional anticancer drugs.3–10 An accurate
understanding of the cross-talk between signaling in CRC-SC
could allow the development and the clinical use of effective
therapies to enhance CRC drug sensitivity. In CRC-SC
β-catenin signaling pathway promotes tumor growth, and
progression by sustaining stem cell expansion.11–14 A key
property of CRC-SC with activated β-catenin signaling is the
protection against conventional chemotherapeutics.2,15 The
molecular mechanisms responsible of the fine-tuning of
β-catenin-mediated stemness and drug response remain
largely unexplored but represent a potentially promising area
for novel therapeutic interventions. Therefore, drugging
upstream signaling molecules endowed with functions that
regulate β-catenin activity may represent a novel approach to
sensitize to chemotherapy. In this context, endothelin-1 (ET-1)
elicits pleiotropic effects in tumor cells and in the host
microenvironment, modulating the epithelial-to-mesenchymal
transition (EMT), the expansion of vascular network and
immune response.16 ET-1 acts through autocrine and para-
crine signaling by binding two distinct receptors: endothelin A
(ETAR) and B (ETBR), which belong to the G-protein-coupled
receptor family. The activation of ET-1/ETAR axis is recognized
as a common mechanism underlying the progression of
various solid tumors, including CRC.16–18 In CRC, the
components of the ET-1 system are expressed not only by
tumor cells, but also by microenvironmental elements, such
as fibroblasts, endothelial cells and macrophages.17–26
Increased levels of ET-1 have been detected in plasma and
tissue samples from patients with CRC.19,20 Moreover, in CRC
the ET-1 gene regulation is directly upregulated by β-catenin.27
Microarray molecular profiling and real-time PCR on CD133+
fractions of CRC lines revealed that ET-1 transcripts are highly
expressed compared with CD133− counterparts.28 A preclini-
cal study in CRC demonstrated that zibotentan, a selective
ETAR antagonist, suppressed tumor growth and progression
indicating a potential role of this antagonist as adjuvant
therapy.29 More recently in CRC cells, it has been demon-
strated that overexpression of the ET-1 gene is a determinant
of acquired resistance to MEK and PI3K inhibitors.30 However
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themolecular mechanism of ET-1 axis to protect against drugs
treatment in CRC remains elusive.
In our recent studies, we reported that ET-1/ETAR axis,
through the contribution of the scaffold protein β-arrestin1
(β-arr1), appears to be critical in the signaling cross-talk,
providing a mechanism of escape to a new less-adverse
niche, in which evasion of drug-induced apoptosis ensures cell
survival required for tumor progression.16,31–35 In this regard,
ET-1 has been recently identified as a key component that
sustains maintenance and clonal expansion of cardiovascular
stem cells population.36 Moreover, a recent report suggests
that β-arr1 has an important protective role, reducing the
chemotherapy-induced intestinal stem cell apoptosis.37 To
dissect the intricate interplay between ET-1R/β-arr1 and
β-catenin, here we report a ET-1R/β-arr1-mediated epigenetic
mechanism in regulating β-catenin signaling to promote EMT
and protection against chemotherapy. Understanding whether
targeting ET-1R/β-arr1 connected with β-catenin pathway in
CRC-SC can restore sensitivity to chemotherapy, is thus
essential to develop more effective strategies in this
malignancy.
Results
Expression of ET-1R/β-arr1 axis in CRC-SC. We first
evaluated the expression of ET-1 axis in CRC-SC features,
by using a panel of patient-derived CRC-SC isolated from
human tumor samples (CC09, CSC5, CSC2 and CSC1), all
carrying APC gene mutations.3,10,12 The mRNA and protein
expression analysis showed that all CRC-SC expressed ET-1
and its receptors, ETAR and ETBR, and released high levels
of ET-1, within the physiologically range needed for the
activation of ET-1R in an autocrine manner38 (Figures 1a–c).
To explore the role of β-arr1 to create intracellular signaling
cross-talk upon ET-1R activation, we first evaluated β-arr1
expression in CRC-SC. These cells expressed β-arr1 both at
mRNA and protein levels (Figures 1a and b). After ET-1
stimulation, we observed an increase of CRC-SC viability,
which was reduced after treatment with macitentan, a potent
ETAR antagonist with significant affinity for ETBR. The same
effect was observed after β-arr1 silencing (Figure 1d and
Supplementary Figure S1a and S2). When cultured in stem
cell medium, CRC-SC grow in large round, unattached
floating spheroid colonies (sphere). As shown in Figure 1e,
whereas the ET-1 addition enhanced the CRC-SC sphere
formation ability, increasing not only the sphere number but
also the size, macitentan treatment negatively affected the
stemness property of CRC-SC, indicating that the ET-1R/β-
arr1 axis sustains CRC-SC features.
ET-1R/β-arr1-driven EMT and invasive behavior in
CRC-SC. Next, we analyzed whether the features of
CRC-SC driven by ETAR/β-arr1 were associated with
molecular changes consistent with EMT.39–44 To this end
we examined the expression of the epithelial marker
E-cadherin and its transcriptional repressors, Twist and Snail,
as well as the expression of mesenchymal markers, such as
N-cadherin and vimentin. Upon ET-1 stimulus, we observed
an increase of N-cadherin, vimentin, Snail and Twist
expression levels, associated with a concomitant decrease
in E-cadherin expression (Figures 2a and b). In addition, as a
result of macitentan treatment or β-arr1 silencing, restored
E-cadherin expression and inhibited N-cadherin, Snail and
Twist expression were observed (Figure 2b). Concordantly,
the analysis of mRNA levels upon ET-1 stimulation showed
the increased expression levels of Snail and N-cadherin and
the decrease of E-cadherin that were reverted following
macitentan treatment (Figure 2c). Remarkably, macitentan, or
the β-arr1 knockdown, inhibited the ET-1-induced suppres-
sion of E-cadherin promoter activity (Figure 2d) and induction
of Snail promoter activity (Figure 2e). Next, we evaluated
whether the ETAR/β-arr1-driven acquisition of EMT pheno-
type correlates with expression and activation of the
proteolytic enzymes, matrix metalloproteases (MMP), and
with an increase of invasive potential of CRC-SC. As shown
in Figures 2f and g, the ET-1-induced MMP-2 and -9 secretion
and activation were inhibited by macitentan treatment, as well
as β-arr1 silencing, as determined by immunoblotting and
zymography. In this context, as a result of enhanced
proteolitic activity of CRC-SC upon ETAR/β-arr1 signaling
activation, when CRC-SC were silenced for β-arr1 or were
treated with macitentan, the ET-1-induced cell invasion was
significantly impaired compared with control cells (Figure 2h),
providing evidence that ETAR/β-arr1 axis activation may be a
critical event to drive EMTand invasive behavior in CRC-SC.
ET-1R/β-arr1 axis links β-catenin pathway in CRC-
SC. The β-catenin signaling pathway represents an hallmark
of CRC-SC governing the maintenance of stemness.2,11–15
We observed that ET-1 stimulation induced the β-catenin
nuclear translocation, an effect that was inhibited upon
macitentan treatment (Figure 3a), enhancing the levels of
serine/threonine non-phosphorylated β-catenin active form
(Supplementary Figure S3a). We analyzed the nucleocyto-
plasmic shuttling of both β-arr1 and β-catenin in the cytosolic
and nuclear extracts of CRC-SC upon different times of ET-1
stimulation. ET-1 induced a time-dependent nuclear translo-
cation of both proteins with a peak after 30 and 60 min of ET-1
challenge (Figure 3b). Of relevance, this effect was strongly
reduced upon macitentan treatment and β-arr1 silencing
(Figure 3c). Moreover, we analyzed β-arr1 and β-catenin
potential physical interaction in the nucleus, by using co-
immunoprecipitation (IP) assays. β-arr1 bound to β-catenin in
the nuclei of ET-1-treated cells (Figure 3d), and this
interaction was inhibited by macitentan, suggesting that
ET-1R/β-arr1 links β-catenin in the nucleus of CRC-SC that
is hampered by ET-1R blockade. Consistent with these
results, the transcriptional activity of β-catenin, induced by
ET-1 in CRC-SC, was inhibited after treatment with maciten-
tan, or by β-arr1 silencing (Figure 3e and Supplementary
Figure S3b), indicating that ET-1/β-arr1/β-catenin interaction
is necessary for inducing β-catenin/T cell factor 4 (TCF4)
transcriptional activity. Given that ET-1 is also a downstream
target gene of β-catenin/TCF4,27,31,32 by using a reporter
plasmid with ET-1 promoter sequence, containing a functional
TCF binding element (TBE), we demonstrated that ET-1
promoter activity was significantly upregulated after ET-1
stimulation and inhibited when the cells were treated with
macitentan, or silenced for β-arr1 (Figure 3f). Next, through
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chromatin immunoprecipitation (ChIP) assays, we demon-
strated that in CRC-SC, both β-arr1 and β-catenin, together
with TCF4, were recruited on TBE of ET-1 promoter. In
parallel, ET-1 stimulation induced the acetylation of histone 3
at Lysine 27 (H3K27), and the competent recruitment of p300
together with β-arr1 and β-catenin (Figures 3g and h).
Knocking down of β-arr1 or treatment with macitentan
abolished the ET-1-induced effect (Figures 3g and h). Hence,
in response to ET-1R activation, β-arr1 was selectively
enriched with β-catenin on ET-1 promoter and the coopera-
tion between these two proteins enhanced the autoregulatory
β-catenin-mediated transcription of ET-1 gene. In parallel, we
evaluated the influence of the ET-1 axis activation on the
transcription of a set of specific β-catenin/TCF4-target genes,
such as ET-1, Cyclin D1 and Axin 2. As shown in Figure 3i,
the analysis of mRNA showed an upregulation of the levels of
these genes upon ET-1 stimulation, and a considerable
decrease after macitentan treatment. Collectively, our find-
ings highlight the role of ET-1R/β-arr1 signaling to inter-
connect the β-catenin pathway in CRC-SC, to form specific
nuclear complex that regulates hystone acetylation in specific
cromosomal regions, upregulating the transcription of differ-
ent β-catenin target genes, including the self-sustained
ET-1/β-catenin activity, as a magnifying mechanism.
ET-1R blockade sensitizes CRC-SC to standard che-
motherapeutic drugs. In CRC-SC, ET-1R/β-arr1 modulates
cell survival pathways. Thus, the stimulation of CRC-SC with
ET-1 was accompanied with phosphorylation of both p42/
p44MAPK and Akt, and macitentan treatment, or the specific
β-arr1 silencing, significantly decreased the ET-1-mediated
MAPK and Akt activation (Figure 4a and Supplementary
Figure S4a). Because a typical property of CRC-SC is the
resistance to treatment with standard chemotherapeutic
agents, as oxaliplatin (OX) and 5-fluorouracil (5-FU), we
evaluated the response of CRC-SC following exposure to OX
and 5-FU at clinically relevant doses,10 and found that these
cells were poorly responsive to chemotherapeutic drugs-
induced apoptosis even at the highest concentration used
(Figure 4b). The treatment with macitentan or the loss of
β-arr1 in a combination regimen with OX or 5-FU, induced a
more effective reduction of cell vitality (Figure 4c and
Supplementary Figure S4b). Furthermore, CRC-SC that
overexpressed exogenous β-arr1-FLAG showed a greater
poor sensitivity to OX or 5-FU, compared with parental cells
(Figure 4d and Supplementary Figure S1b), suggesting that
ETAR/β-arr1 blockade might sensitize CRC-SC to OX and
5-FU-induced apoptosis. Mechanistically, we found that the
combined treatment of macitentan with chemotherapeutic
agents, resulted in an enhanced expression of the poly
ADP-ribose polimerase (PARP) cleaved form (Figure 4e and
Supplementary Figure S4c). In addition, we found that ET-1
increased the expression of the prosurvival factor Bcl-XL,
which was strongly reduced upon macitentan and OX
co-treatment (Figure 4f). This implies that the activation of
ET-1R/β-arr1 survival signaling is involved in the protection
of CRC-SC against chemotherapeutics, suggesting that
Figure 1 Expression of ET-1/β-arr1 axis in CRC-SC. (a) In a panel of patient-derived CRC-SC (CC09, CSC5, CSC2 and CSC1), expression of ET-1, ETAR, ETBR and β-arr1
mRNA copy number was analyzed by real-time PCR (qPCR) normalized using endogenous cyclophilin-A. Values are shown as mean± S.D. from three independent experiments
repeated in triplicates. (b) ETAR, ETBR and β-arr1 protein expression was analyzed by immunoblotting (IB). Tubulin was used as loading control. (c) ET-1 secretion evaluated by
ELISA in 24 h cell-conditioned media. Values are shown as mean± S.D. from three independent experiments repeated in triplicates. (d) Time-dependent effect of treatment with
ET-1 (100 nM) and/or macitentan (MAC) (1 μM) on cell growth of CC09 cells transfected with siRNA negative control (SCR) or with β-arr1 siRNA (si-β-arr1). Values are shown as
mean±S.D. from three independent experiments repeated in triplicates (*Po0.001 versus CTR; **Po0.001 versus ET-1) (e) Sphere formation assay of CSC5 cells, treated with
ET-1 (100 nM) and MAC (1 μM) alone or in combination for 7 days. Values are shown as mean± S.D. from three independent experiments repeated in triplicates (*Po0.05
versus CTR; **Po0.05 versus ET-1). Representative images of tumor spheres were shown in the right panel
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molecular targeting of ET-1R in CRC-SC might improve the
efficacy of chemotherapeutic regimens.
ET-1R blockade inhibits tumor growth and restores
sensitivity to chemotherapy in CRC-SC patient-derived
xenografts. To verify whether ET-1R blockade by macitentan
would also affect tumor growth in vivo, patient-derived CC09
and CSC5 CRC-SC were injected into the flank of mice and
were allowed to grow until they reached a detectable size. The
xenografts obtained were confirmed as colorectal adenocarci-
noma, as showed by hematoxylin–eosin staining in the
representative sections from tumor xenografts (Figure 5a and
Supplementary Figure S5a). Next, we tested the effect of
macitentan alone or in combination with chemotherapy in CRC-
SC xenografts. After the appearance of palpable tumors (day
14 for CC09 xenografts, and day 42 for CSC5 xenografts), mice
were randomized into different groups of ten mice undergoing
the following treatments for 4 weeks: (i) vehicle (control), (ii)
macitentan (30 mg/Kg/oral daily), (iii) OX (0.25 mg/Kg/i.p. once
a week) or 5-FU (15 mg/Kg/i.p daily), (iv) macitentan plus OX or
5-FU. These treatments, were generally well tolerated without
any loss of weight or detectable signs of acute or delayed
toxicity. At the end of 4 weeks of treatment, tumor size of mice
treated with macitentan significantly decreased compared with
vehicle-treated mice (~60% for CC09 xenografts; 55% for
CSC5 xenografts, Po0.02), demonstrating the therapeutic
potential of macitentan in controlling tumor growth. Most
importantly, a synergistic growth-inhibitory effect, as calculated
by Chou and Talalay method, was observed when macitentan
was used in combination with OX, compared with macitentan-
or OX-treated mice (90 versus 68% or 12% respectively, for
CC09; 84 versus 55% or 49% respectively, for CSC5
xenografts; Po0.05) or in combination with 5-FU compared
with macitentan- or 5-FU-treated mice (91 versus 50% or 10%
respectively, for CC09 xenografts; Po0.05, Figure 6), thus
proving the ability of macitentan to sensitize CRC-SC
xenografts to different chemotherapeutic drugs. Moreover, the
therapeutic effects of macitentan were long-lasting, both in
monotherapy or combination with chemotherapeutic drugs, for
up to 2/3 weeks after termination of treatments. Indeed, we still
found a persisted tumor growth reduction even during the
treatment-free period in mice treated with macitentan com-
pared with vehicle-treated mice (46% at day 63, for CC09
xenografts, Figure 5a; 40% at day 55 for CC09 xenografts,
Figure 6; 61% at day 77 for CSC5 xenografts, Supplementary
Figure S5a; Po0.02), and a persistent synergistic inhibitory
effect in combinatorial regimes (91 versus 46% for macitentan
or 37% for OX, for CC09 xenografts; 89 versus 40% for
Figure 2 ET-1R/β-arr1 axis drives EMT process in CRC-SC. (a) Lysates from CC09 cells were analyzed by IB for the expression of epithelial (E-cadherin) and mesenchymal
(N-cadherin, Snail, and vimentin) markers after ET-1 (100 nM) stimulation for 24 h. Tubulin was used as loading control. (b) Lysates from CC09 cells transfected with SCR or si-β-
arr1 and treated for 24 h with ET-1 (100 nM) and/or MAC (1 μM) were analyzed by IB for the expression of E-cadherin, N-cadherin Snail and Twist. Tubulin was used as loading
control. (c) Snail, E-cadherin, and N-cadherin expression in CC09 cells upon ET-1 (100 nM) and/or MAC (1 μM) treatment evaluated by qPCR, normalized using endogenous
cyclophilin-A. Values are shown as mean± S.D. from three independent experiments repeated in triplicates (*Po0.002 versus CTR; **Po0.005 versus ET-1). (d) E-cadherin
promoter activity and Snail promoter activity (e) evaluated in CC09 cells transfected with SCR or si-β-arr1 and treated for 24 h with ET-1(100 nM) and/or MAC (1 μM). Values are
shown as mean±S.D. from three independent experiments repeated in triplicates (*Po0.01 versus CTR; **Po0.001 versus ET-1 in SCR-transfected cells). (f) Lysates from
CC09 cells transfected with SCR or si-β-arr1 treated with ET-1 (100 nM) and/or MAC (1 μM) for 24 h were analyzed for MMP-2 and -9 by IB. Tubulin was used as loading control.
(g) Conditioned media collected from CCO9 treated as in (f) were used to determine the secretion and activity of MMP-2 and -9 by gelatin zymography. (h) Cell invasion assay of
CC09 cells transfected with SCR or si-β-arr1 and exposed to ET-1 (100 nM) and/or MAC(1 μM) for 24 h. Values are shown as mean±S.D. from three independent experiments
repeated in triplicates (*Po0.002 versus CTR; **Po0.001 versus ET-1 in SCR-transfected cells). Representative images of invading cells were shown in the right panel
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macitentan or 20% for 5-FU, for CC09 xenografts, and 83
versus 61% for macitentan or 57% for OX, for CSC5
xenografts; Po0.05). In parallel, immunoblotting analysis of
tumor xenografts of mice co-treated with macitentan and OX
showed a marked effect in reducing MAPK and Akt activation,
and a reversion of EMT effectors compared with controls
(Figures 5b and c and Supplementary Figures S5b and c).
These findings indicate that blockade of ET-1R with macitentan,
in combination with chemotherapeutic drugs, controls EMT
aggressive phenotype of CRC-SC, thus increasing sensitivity
to the chemotherapy and promoting tumor regression.
Discussion
The presence of stem cell-like cells has been recognized as
the main cause of failure in the treatment of several
malignancies.5,6 It is therefore evident that a therapeutic
approach to target CSC pool could be more effective to
eradicate tumor. Drug sensitivity is frequently associated with
dysregulation of a signaling network rather than of a single
pathway. In the present study, we provide evidence that ET-1R/
β-arr1 links β-catenin signaling to sustain CRC-SC features,
also through the amplification of ET-1 autocrine loop, outlining
a model in which ET-1 interlinks β-catenin signaling to support
progression and recurrence of CRC. The findings presented
here reveal that ET-1R/β-arr1 axis has a critical role in CRC-
SC signaling and chemoprotection. Notably, ET-1R blockade
by macitentan markedly affected the signaling cross-talk
mediated by β-arr1 involved in the maintenance of CRC-SC
and drug response. Specifically, ET-1R blockade results
in a strong decrease of survival Akt/MAPK signaling
pathways,45,46 with the consequent reduction of cell growth
Figure 3 ET-1R/β-arr1 axis induces β-catenin pathway in CRC-SC. (a) β-catenin localization evaluated by immunofluorescence staining (green) in CC09 cells stimulated for
30 min with ET-1 (100 nM) alone or in combination with MAC (1 μM). Nuclei were counterstained with DAPI (blue) (scale bar, 10 μm). (b) IB analysis for β-catenin and β-arr1
protein expression in cytoplasmic and nuclear extract of CC09 cells treated with ET-1(100 nM) for the indicated times. HSP-70 and PCNA were used as cytoplasmic and nuclear
loading control, respectively. (c) IB analysis for β-catenin and β-arr1 protein expression in nuclear extracts of CC09 cells transfected with SCR or si-β-arr1 and treated for 30 min
with ET-1 (100 nM) and/or MAC (1 μM). Histone H3 (H3) was used as loading control. (d) Nuclear extracts of CC09 cells, treated for 30 min with ET-1 (100 nM) and/or MAC
(1 μM), were immunoprecipitated (IP) with anti-β-arr1 or with irrelevant IgG (IgG) and immunoblotted with anti-β-catenin and anti-β-arr1. H3 was used as loading control.
(e) β-catenin transcriptional activity evaluated in CC09 cells transfected with SCR or si-β-arr1 and treated for 24 h with ET-1 (100 nM) and/or MAC (1 μM). Values are shown as
mean±S.D. from three independent experiments repeated in triplicates (*Po0.001 versus CTR; **Po0.002 versus ET-1 in SCR-transfected cells). (f) ET-1 promoter activity
evaluated in CC09 cells treated as in (e). Values are shown as mean± S.D. from three independent experiments repeated in triplicates (*Po0.001 versus CTR; **Po0.001
versus ET-1 in SCR-transfected cells). ChIP analysis performed in CC09 cells treated for 30 min with ET-1 (100 nM) and/or MAC (1 μM) (g) or in CC09 cells transfected with SCR
or si-β-arr1 and treated for 30 min with ET-1 (100 nM) and/or MAC (1 μM) (h). Chromatin was incubated with β-arr1, β-catenin, p300, H3K27ac and TCF4 Abs and analyzed by
PCR analysis by using specific primers for ET-1 promoter. Non-specific immunoglobulin G (IgG) was used as irrelevant Ab (IRR). The input DNA lane represents one-twentieth of
the precleared chromatin used in each ChIP reaction. (i) ET-1, Cyclin D1 and Axin 2 mRNA expression in CC09 cells stimulated for 24 h with ET-1 (100 nM) alone or in
combination with MAC (1 μM) evaluated by qPCR, normalized using endogenous cyclophilin-A. Values are shown as mean± S.D. from three independent experiments repeated
in triplicates ( *Po0.01 versus CTR; **Po0.05 versus ET-1)
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Figure 4 ET-1R blockade sensitizes CRC-SC to standard chemotherapeutic drugs. (a) Lysates from CC09 cells treated for 1 h with ET-1 (100 nM) and/or MAC (1 μM) and
transfected with SCR or with si-β-arr1 were immunoblotted with anti-pp42/44MAPK, anti-p42/44MAPK, anti-pAkt and anti-Akt. (b) Effect of exposure to different concentrations of
oxaliplatin (OX) and 5-fluorouracil (5-FU) after 24 h on cell vitality of CC09 cells. (c) Time-dependent effect of treatment with MAC (1 μM) or OX (100 μM) or 5-FU (50 μg/ml) alone
and combination, for 24 h on cell growth of CC09 cells transfected with SCR or with si-β-arr1. Values are shown as mean± S.D. from three independent experiments repeated in
triplicates (*Po0.001 versus CTR; **Po0.001 versus OX; ***Po0.002 versus 5-FU). (d) Effect of treatment with OX (100 μM) or 5-FU (50 μg/ml), for 24 h on cell growth of
CC09 cells transfected with empty vector (Mock) or with β-arr1-FLAG. Values are shown as mean± S.D. from three independent experiments repeated in triplicates (*Po0.002
versus CTR; **Po0.002 versus chemotherapy-treated cells). (e) IB analysis of PARP cleaved form (cl PARP) in CC09 cells treated for 24 h with MAC (1 μM) or OX (100 μM) or 5-
FU (50 μg/ml) alone and combination. Tubulin was used as loading control. (f) IB analysis of Bcl-XL in CC09 cells treated for 24 h with ET-1 (100 nM) or MAC (1 μM) or OX
(100 μM) alone and combination. Tubulin was used as loading control
Figure 5 ET-1R blockade by macitentan inhibits tumor growth and restores sensitivity to oxaliplatin in CRC-SC xenografts. (a) CC09 cells (5 × 105) were injected s.c. into the
flank of nude mice. When tumors were detected, mice were treated with vehicle (CTR), or MAC (30 mg/Kg/oral daily), or OX (0.25 mg/Kg/i.p. once a week), or MAC (30 mg/Kg/
oral daily) with OX (0.25 mg/Kg/i.p. once a week) combination for 4 weeks. The comparison of the time course of tumor growth curves by two-way ANOVA with group-by-time
interaction for tumor growth was statistically significant (Po0.02). Data points, averages± S.D. The upper panels represented the hematoxylin–eosin staining of transplanted
tumor xenografts (scale bar, 50 μm) or the images of tumors from each treatment group. (b) Expression of pp42/44MAPK, p42/44MAPK, pAkt and Akt as evaluated by IB on total
extracts from tumors of CC09 xenografts. (c) E-cadherin, N-cadherin, Snail and vimentin, evaluated by IB of total extracts from tumors of CC09 xenografts
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and apoptosis induction. From a molecular standpoint, the
hallmark of CRC-SC has been shown to be the abnormal
activation of β-catenin signaling pathway and subsequent
nuclear β-catenin accumulation.2,11–15 β-catenin and ET-1R
signaling pathways are critically involved in the progression of
CRC. Our study discloses multi-point cross-talk between
β-catenin and ET-1R/β-arr1 pathway in CRC-SC, indicating a
promising therapeutic strategy for CRC patients. We describe
the mechanistic link between ET-1 and β-catenin through the
specific interaction with β-arr1. Notably, β-arr1 acts as a
transcription co-activator that forms a complex with β-catenin/
TCF and co-bind target genes, including ET-1. Indeed we
reveal that, in response to ET-1R activation, β-arr1 could
control two aspects of β-catenin nuclear functions: nuclear
accumulation and assembly of a transcriptional complex.
Consistent with a role of functional hub to organize nuclear
complex, β-arr1 promotes the recruitment of p300 with TCF on
ET-1 proximal promoter, and histone modification associated
with ET-1 gene transcription. Macitentan interfered the
functional interplay between β-catenin and ETAR/β-arr1,
suppressing the transactivation of TCF4 that is essential for
target gene transcription. Therefore, based on our findings, we
may hypothesize that ET-1R blockade might modulate the
ET-1 signaling that controls the preferences of β-arr1 engage-
ment, such as β-catenin, which can act to convey a persistent
feedback protective ET-1 autocrine loop that sustains poor
drug sensitivity, EMT and invasive features.47 Our data
reinforce the notion that ET-1R is an important driver in
CRC,17–29 indicating ET-1R as novel therapeutic targets for
CRC. Interestingly, ET-1R blockade bymacitentan may have a
dual anti-ET-1R and anti-β-catenin activity that might be
therapeutically explored. In this context, our results obtained
in CRC preclinical models, indicated that macitentan, interfer-
ing with the epigenetic mechanism utilized by ET-1R/β-arr1 to
regulate β-catenin-driven signaling and survival pathways,
significantly improves the efficacy of OX and 5-FU-based
regimens, preventing the tumor growth and increasing the
sensitivity of CRC-SC to the cytotoxic agents. Much of the
plasticity associated with CRC-SC arises from the local niche,
highlighting the regulatory effects of the tumor microenviron-
ment. In this regard, the potential advantage of using the dual
ETAR/ETBR antagonist macitentan is to target not only CRC,
which express mainly ETAR,
17–29 but also tumor-associated
stromal elements, such as vascular, lymphatic and inflamma-
tory cells and fibroblasts, which all express ETBR.
16,31 ETBR
signaling is pro-angiogenic and may also impair antitumour
immunity by preventing the maturation and function of
dendritic cells, which are pivotal for the initiation of T cell-
mediated immune responses and the homing of T cells to
tumors.48,49 Therefore, the FDA approved small molecule
macitentan, interfering with both ETAR andETBR,might offer a
more efficacious therapeutic strategy in combination with
clinical cytotoxic drugs, because it might target aggressive
CRC-SC, disabling multiple signaling circuits activated by
ETAR/β-arr1 axis and microenvironment-associated elements
expressing ETBR, offering also the opportunity to enhance
antitumor immune response.50–53 Of note, the cancer genome
atlas (TCGA) RNAseqv2 data show high mRNA levels of
ETAR, as well as of β-catenin, in colon adenocarcinoma
samples (n=459) compared with normal colon tissues
(n=41), as displayed with FireBrowse. The mRNA expression
of ETAR and β-catenin was significantly upregulated in tumor
samples compared with normal (P= 1.0554e-13 and
P= 7.3709e-11, respectively, as evaluated by Wilcoxon rank-
sum test). We propose that high expression levels of ETAR
function in CRC, at least in part, through the connection of
β-catenin pathway. The preclinical data demonstrating that the
combined treatment of macitentan and OX or 5-FU effectively
reduced tumor growth suggest that CRC patients with tumor
that overexpress ETAR and β-catenin may benefit from this
combination therapy. Therefore, targeting ET-1R, empowering
the β-catenin/ET-1 circuit, can represent a necessary measure
to reach clinical efficacy for combination therapy in CRC
patients. Macitentan can represent an opportunity to block
connections between signaling pathways that interfere with
chemotherapy drug efficacy in CRC. Our demonstration of
non-canonical cross-talk between β-catenin and ET-1R/β-arr1
may have far-reaching implications in CRC and in other
tumors in which ET-1R signaling is important. These data
complement and add greater relevance to previous studies in
ovarian,31,51–53 gliobastoma,50 as well as breast and lung
cancer brain metastasis models,54 demonstrating that,
regardless of the cancer type, ET-1R might represent a
vulnerability node that should be blocked to enhance
sensitivity to chemotherapy. Taken together, our study
identified ET-1R/β-arr1 as an important actionable node,
demonstrating that ET-1R blockade by macitentan not only
inhibits tumor growth of xenografts but also sensitizes these to
chemotherapeutic agents, revealing a new prospective on the
CRC patient treatment.
Materials and Methods
Materials. ET-1 was (Bachem, Bubendorf, Torrance, Switzerland) and it was
used at 100 nM and incubated with the cells for the indicated times. Macitentan
(MAC), also N-(5-[4–bromophenyl]-6-{2-[5–bromopyrimidin–2–yloxy]ethoxy}pyrimi-
din-4-yl)-N’-propylsulfamide, (Actelion Pharmaceuticals, Allschwil, Switzerland).
Pre-treatment of cells with MAC, was used at the concentration of 1 μM for
30 min prior to the addition of ET-1. Oxaliplatin (SUN PHARMA, Goregaon (E),
Mumbai) used at 100 μM and Fluorouracil (5-FU) (TEVA, Petach Tikva, Israel),
used at 50 μg/ml.
Figure 6 Macitentan inhibits tumor growth and restores sensitivity to 5-FU in
CRC-SC xenografts. CC09 cells (5 × 105) were injected s.c. into the flank of nude
mice. When tumors were detected, mice were treated with vehicle (CTR), or MAC
(30 mg/Kg/oral daily), or 5-FU (15 mg/Kg/i.p daily), or MAC (30 mg/Kg/oral daily) with
5-FU (15 mg/Kg/i.p daily) combination for 4 weeks. The comparison of the time
course of tumor growth curves by two-way ANOVA with group-by-time interaction for
tumor growth was statistically significant (Po0.05). Data points, averages± S.D.
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Cell culture. The patient-derived CRC-SC enriched cultures (CC09,CSC5,
CSC2 and CSC1), isolated from human tumor samples and capable to reproduce a
histological copy of the original patient tumor when inoculated in immunocompro-
mised mice, were kindly provided by the Istituto Superiore di Sanità (ISS) CSC
biobank.3,10,12 Cells were cultured in ultra-low attachment plates and maintained in
stem cell medium (DMEM/F12, supplemented as reported in ref. 10) and monthly
tested for mycoplasma contamination. Genomic analysis of CRC-SC showed that
CC09 carried mutant BRAF, PIK3CA, APC, TP53 and SMAD4; CSC5 carried
mutant KRAS, PIK3CA, APC and SMAD4; CSC2 carried mutant KRAS, APC, TP53
and SMAD4; CSC1carriedmutant PIK3CA, APC and SMAD4 (ref. 3) and
unpublished results.
Immunoblotting analysis. Whole-cell lysates of CRC-SC were prepared
using a ice-cold modified RIPA buffer (50 mM Tris-HCl pH 7.4, 250 mMNaCl, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing a mixture of protease
and phosphatase inhibitors or NE-PER nuclear and cytoplasmic extraction reagents
(Termo Fisher Scientific, Waltham, USA) to separate cytoplasmic and nuclear
fractions. Protein content of the extracts was determined using protein assay kit
(Bio-Rad, Hercules, CA, USA) and resolved by SDS-PAGE. Immunoblotting of Abs
specific for β-arr1 (K-16: sc-9182), β-Catenin (E-5: sc-7963), tubulin (DM1A: sc-
32293), MMP-2 (K-20: sc-8835 ), MMP-9 (M-17: sc-6841), Snail (E-18: sc-10432),
vimentin (C-20: sc-7557), Histone H3 (C-16: sc-8654), PCNA (F-2: sc-25280),
(Santa Cruz Biotechnology Dallas, TX, USA), HSP-70 (Enzo Life Sciences, New
York, USA, ADI-SPA-812), Twist (ab50581), ETAR (ab178454), ETBR (ab39960)
(Abcam, Cambridge, UK), AKT (9272) pAKT (Ser-473) (9271), p44/42MAPK
(9102), pp42/44MAPK (4377), cleaved-PARP (9541), non-phospho (active) β-
Catenin (Ser33/37/Thr41) (4270) (Cell Signaling, Beverly, MA, USA), N-cadherin
(610920), E-cadherin (610181) (BD Biosciences, Franklin Lakes, NJ, USA) were
detected using HRP-conjugated anti-mouse or anti-rabbit Abs (Pierce, 31460) and
visualized by enhanced chemiluminescence detection system (ECL, Bio-Rad).
Immunoprecipitation analysis. Nuclear extracts were immunoprecipitated
as previously described,31 using β-arr1, or non-specific immunoglobulin G (IgG) (Santa
Cruz Biotechnology) and protein G-agarose beads (Thermo Fisher Scientific) at 4 °C
overnight. Immunoprecipitates were resolved by SDS-PAGE and the proteins were
detected by IB with the following Abs: β-Catenin, β-arr1 and Histone 3 (Santa Cruz
Biotechnology). To obtain clean and specific IB signals of β-arr1 which run very close
to heavy chain of IgG, we used HRP-conjugated protein A (Thermo Scientific,
Waltham, MA, USA) instead of HRP-conjugated secondary Ab.
RNA silencing and transfection. For the silencing of β-arr1, the CRC-SC
were transiently transfected with ON-TARGET plus Human ARRB1 siRNA-SMART
pool, containing four different siRNAs targeting β-arr1 (Dharmacon, Lafayette, CO,
USA). The ON-TARGET plus Control Non-targeting siRNA (Dharmacon) was used
as negative control. For exogenous expression of β-arr1 we used pcDNA3-β-arr1-
FLAG (wild-type) plasmid vector, containing a ‘wobble’ mutant construct encoding
rat β-arr1 sequences resistant to small interfering RNA targeting, kindly provided by
Dr. Robert Lefkowitz (Howard Hughes Medical Institute, Duke University, Durham,
NC,USA). Cells transfected with the empty vector pcDNA3 were used as negative
control (Mock).
RNA isolation and qPCR. Total RNA was isolated using Trizol (Thermo
Fisher Scientific) according to the manufacturer’s protocol. RNA was reversed
transcribed using Super Script VILO cDNA synthesis kit (Thermo Fisher Scientific).
Quantitative real-time PCR (qPCR) was performed by using LightCycler rapid
thermal cycler system (Roche Diagnostics, Basel, Switzerland) and 7500 Fast real-
Time PCR System (Thermo Fisher Scientific). The expression levels of mRNA were
determined by normalizing to cyclophilin-A mRNA expression. Each PCR analysis
was done twice separately. Final data were obtained by using 2−ΔΔCt method.
The primers sets used were as follows: ET-1 F: CACCGAATTCGAATGTGAC and
ET-1R: 5'-TCCTCTGCTGGTTCCTGACT-3'; ETAR F: 5'-GTCTGCTGTGGGCA
ATAGTTG-3' and ETAR R: 5'-GCTTCCTGGTTACCACTCATCAA-3'; ETBR R: 5′-
TCCCGTTCAGAAGACAGCTT-3′ and ETBR R: 5′-CAGAGGGCAAAGACAAGGAC
-3'; β-arr1 F: 5'-CAGTATGCAGACATCTGCCTTT-3' and β-arr1 R: 5'-AGTTC
GTGTCTTCGTGCT-3'; E-cadherin F: 5'-CCCACCACGTACAAGGGTC-3' and
E-cadherin R: 5'-ATGCCATCGTTGTTCACTGGA-3'; N-cadherin F: 5'-GGTGGAG
GAGAAGAAGACCAG-3' and N-cadherin R: 5'-GGCATCAGGCTCCACAGT-3'; Snail
F: 5'-CACTATGCCGCGCTCTTTCC-3' and Snail R: 5'-GTCGTAGGGCTGC
TGGAAG-3'; Axin 2 F: 5'-CTGGCTTTGGTGAACTGTTG-3' and Axin 2R: 5'-CTGG
CTTTGGTGAACTGTTG-3'; Cyclin D1 F: 5'-CTAATGGAATGGTTTGGGAATATCC
ATGTA-3' and Cyclin D1 R: 5'-AAAGGAACTTATCATCCTGGCAAT-3'; Cyclophilin-A
F: 5'-TTCATCTGCACTGCCAAGAC-3' and Cyclophilin-A R: 5'-TCGAGTTGTCCA
CAGTCAGC-3'.
Chromatin immunoprecipitation. Chromatin was extracted from CRC-CS
cells (5 × 106) and ChIP assays were performed as previously described.31 The
differential binding between proteins and promoter DNA was examined by PCR. The
primary Abs used were as follows: anti-β-catenin (E-5: sc-7963), anti-β-arr1(K-16:
sc-9182), anti-p300 (N-15: sc-584), TCF4 (H-125: sc-13027) (Santa Cruz
Biotechnology) anti-acetylated Histone H3 (Lys 27) (Millipore, Billerica, MA, USA,
07-360). The primers used were as follows: ET-1 promoter 5′-CAGCTTGCAA
AGGGGAAGCG-3′ and 5′-TCCGACTTTATTCCAGCCCC-3′.
Luciferase reporter gene assay. The CRC-SC were transiently trans-
fected, using Lipofectamine 2000 (Thermo Fisher Scientific) according to
manufacturer’s instructions, with pGL3-SNA (−869/+59) construct (kindly provided
by Dr. A. Garcia de Herreros, Institut Municipal d’Investigació Mèdica, Universitat
Pompeu Fabra, Barcelona, Spain) or with pGL2-Ecad3 construct (kindly provided by
Dr. E.R. Fearon, University of Michigan, Ann Arbor, MI, USA), respectively
containing luciferase gene under the control of the human Snail and E-cadherin
promoter, and with pCMV-β-galactosidase vector (Promega, Madison, WI, USA).
Transcriptional activity of β-catenin/TCF was evaluated by transient transfection of
CRC-SC with TOP/Flash luciferase reporter, containing multiple TCF4 binding sites
for β-catenin and FOP/Flash luciferase reporter (negative control) (results were
expressed as the ratio of TOP/Flash over FOP/Flash activity) and pCMV-β-
galactosidase vector. To measure the ET-1 promoter activity, the human CRC-SC,
were transiently co-transfected with ET-1 promoter reporter sequence, spanning
− 1300 to +230 bp surrounding the transcriptional initiation site and containing a
functional TBE located at –73 to –67 bp, kindly provided by Dr. Z. Zhang (University
of California San Diego School of Medicine, La Jolla, CA, USA), and pCMV-β-
galactosidase vector. Reporter activity was measured using the Luciferase assay
system (Promega) and normalized to β-galactosidase activity.
Gelatin zymography. To detect MMP-9 and -2 activity in conditioned media,
CRC-SC transiently transfected with si-β-arr1 or with negative control, were
stimulated with ET-1 or MAC, alone or in combination for 24 h. Conditioned media
was collected and concentrated by using Spin-X UF concentrator columns (Corning,
New York, NY, USA ). Conditioned medium was separated by 9% SDS-PAGE gels
containing 1 mg/ml gelatin. The gels were washed for 30 min at 22 °C in 2.5% Triton
X-100 and then incubated in 50 mM Tris (pH 7.6), 1 mM ZnCl2, and 5 mM CaCl2 for
18 h at 37 °C. After incubation the gels were stained with 0.2% Coomassie Blue.
Enzyme-digested regions were identified as white bands on a blue background and
quantified by computerized image analysis of the band. Molecular sizes were
determined from the mobility, using gelatin zymography standards (Bio-Rad
Laboratories, Richmond, CA, USA).
Invasion assay. Chemoinvasion assays were carried out using modified
Boyden Chambers consisting of transwell membrane filter inserts with 8 μm size
polycarbonate membrane precoated with polymerized collagen placed in a 24-well
plate (BD Biosciences). The human CRC-SC clones transiently transfected with
si-β-arr1 or with negative control, were stimulated with ET-1 or MAC, alone or in
combination with ET-1, added to the lower chamber. The cells were left to migrate
for 24 h at 37 °C. Cells on the upper part of the membrane were scraped using a
cotton swab and the migrated cells were stained using Diff-Quick kit (Merz-Dade).
The experiment was performed in triplicates for all conditions described. From every
transwell, several images were taken under a phase-contrast microscope at × 10
magnification and two broad fields were considered for quantification. The results of
the analysis of the individual photos are depicted as dots in the various graphs,
normalized to control and shown as fold of control.
ELISA. The release of ET-1 in media of CRC-SC was measured in triplicate on
microtiter plates by using an ELISA kit (Phoenix Pharmaceuticals, Burlingame, CA,
USA) according to the manufacturer's instructions.
Cell viability analysis. The human CRC-SC were seeded in triplicates, in
24-well plates. The cells were transiently transfected with si-β-arr1 or β-arr1-FLAG
or with specific negative control and treated with ET-1, MAC, OX and 5-FU, alone or
in combination. After 24 or 48 or 72 h cell viability was determinated by counting the
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cells, for each time point, using a Neubauer-counting chamber and a bright field
miscroscope. The trypan blue dye exclusion method was used to evaluate the
percentage of viable cells.
Clonogenic assay. The CRC-SC tumor spheres were mechanically
dissociated and the resulting cells were seeded at low densities (1000 cells/ml)
in 12-well low adhesion plates at 1 ml per well, in stemness medium with or without
ET-1 or MAC, alone or in combination. After 7 days of growth, the tumor spheres
obtained were analyzed and quantified by a phase-contrast microscope at × 10
magnification.
CRC-SC xenografts. Athymic (nu+/nu+) mice, 5- to 6-week of age (Charles
River Laboratories, Milan, Italy), were subcutaneously injected with 5x105 viable
CRC-SC, in 100 μl PBS/Matrigel (BD Biosciences) into the flank, following the
guidelines of the Italian Ministry of Health. For all the CRC-SC, xenografts were
detectable within 2–6 weeks. Tumor xenografts were extracted, formalin-fixed, and
paraffin-embedded. Haematoxylin–eosin-stained sections were subsequently
evaluated by a pathologist in comparison with human tumors. For drug testing,
5 × 105 viable CRC-SC, in 100 μl PBS/Matrigel, were subcutaneously injected into
the flank of mice and were allowed to grow until they reached a detectable size.
Drug treatments were started when tumors were detected, mice were randomized
into different groups of 10 mice undergoing the following treatments for 4 weeks: (i)
vehicle (control), (ii) macitentan (30 mg/Kg/oral daily), (iii) OX (0.25 mg/Kg/i.p. once
a week) or 5-FU (15 mg/Kg/i.p daily), (iv) macitentan plus OX or 5-FU. Tumor
volume was measured with caliper and the tumor growth curves were plotted. Tumor
volume was calculated using the formula: π/6 larger diameter × (smaller diameter).2
At the end of experiments all mice were euthanized and tumors were harvested and
preserved for further analysis.
Statistical analysis. Statistical analysis was performed using Student’s t-test
and Fisher’s exact test to compare in vitro experiments. The time course of tumor
growth was compared across the groups using two-way ANOVA, with group and
time as variables. All statistical tests were carried out using SPSS software (SPSS
11, SPSS Inc. Chicago, IL, USA). A two-sided probability value of o0.05 was
considered statistically significant. The Wilcoxon rank-sum test was used to analyze
the gene expression obtained from TCGA of colon adenocarcinoma samples.
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